The phase 2 ZZFIRST trial met its primary PSA response end point with enzalutamide plus talazoparib in high-volume mHSPC, though the triplet showed added toxicity.
Commentary|Articles|December 4, 2025
Experts Preview Anticipated HER2-Positive Breast Cancer Data Ahead of SABCS 2025
Author(s)Jax DiEugenio
Fact checked by: Chris Ryan
Leading experts highlight key HER2-positive studies ahead of SABCS 2025.
Advertisement
Advertisement
As anticipation builds for this year’s San Antonio Breast Cancer Symposium (SABCS), OncLive® asked leading breast cancer specialists to share the HER2-positive research topics they are most eager to follow at this year’s meeting.
Related to this article
Sara Nunnery, MD, MSCI, and Kelly E. McCann, MD, PhD, discuss practice-changing data with T-DXd for HER2-positive breast cancer.
Neoadjuvant PD-1–based immunotherapy plus chemotherapy produced pCRs across 3 cohorts in resectable locally advanced HNSCC.
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Daniel Boiarsky, MD, and William Phillips, MD, discuss findings from studies that they presented during the OncLive National Fellows Forum: Lung Cancer.
Neeta Somaiah, MD, discusses the significance of the Peak study and what an approval of bezuclastinib plus sunitinib would mean for GIST.
Sara Nunnery, MD, MSCI, and Irene M. Kang, MD, discuss toxicity and monitoring considerations for the use of ADCs in metastatic TNBC.
The NMPA accepted the NDA for the PD-L1/4-1BB–directed bispecific antibody opamtistomig in previously treated advanced extrapulmonary NEC.
Advertisement
Advertisement